Results 11 to 20 of about 21,933 (136)

Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS [PDF]

, 2011
The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C(
Iqbal, Zafar, Watson, David, Holyoake, Tessa, Elliott, Moira, Jørgensen, Heather   +4 more
core   +13 more sources

Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1

Clinical Case Reports (discontinued), 2020
Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c‐NFs) and promote growth of pre‐existing c‐NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.
Yoshimasa Nobeyama
exaly   +2 more sources

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate

Pharmaceutics, 2019
The proposed study examined the characterization and stability of solid-state amorphous imatinib mesylate (IM) after 15 months under controlled relative humidity (60 ± 5%) and temperature (25 ± 2 °C) conditions. After 2 weeks, and 1, 3, 6,
Dominik M Marciniak, Agata Górniak, Bozena Karolewicz   +2 more
exaly   +3 more sources

Evaluation of the anticancer activity of dipyridamole and Imatinib mesylate compounds against breast cancer cell line and related biochemical and genetic changes [PDF]

Journal of Bioscience and Applied Research, 2021
Imatinib mesylate and dipyridamole were antineoplastic targeted chemotherapeutic agents, and it is here evaluating the anticancer of imatinib mesylate and dipyridamole compounds against MDA-MB231 breast cancer cell line in-vitro and the related cell ...
Rania El-Leithy, Aly Mohamed, Asmaa EL-refaay, Mohamed Omran   +3 more
doaj   +1 more source

Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects

Clinical and Translational Science, 2022
For the long‐term efficacy of dry eye disease treatment, relieving underlying inflammation is necessary. Imatinib mesylate is a novel ophthalmic formulation of imatinib mesylate, which is expected to alleviate inflammation by inhibiting the discoidin ...
Joo Young Na, Ki Young Huh, Kyung‐Sang Yu, Joon Young Hyon, Hye Cheong Koo, Jong Ho Lee, Ji Chang You, Jae‐Yong Chung   +7 more
doaj   +1 more source

A Modified Electrochemical Sensor Based on N,S-Doped Carbon Dots/Carbon Nanotube-Poly(Amidoamine) Dendrimer Hybrids for Imatinib Mesylate Determination

Biosensors, 2023
Imatinib mesylate, an anticancer drug, is prescribed to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. A hybrid nanocomposite of N,S-doped carbon dots/carbon nanotube-poly(amidoamine) dendrimer (N,S-CDs/CNTD) was successfully ...
Maryam Saleh Mohammadnia, Hossein Roghani-Mamaqani, Masoumeh Ghalkhani, Salar Hemmati   +3 more
doaj   +1 more source

Imatinib mesylate in chordoma [PDF]

Cancer, 2004
AbstractBACKGROUNDTo the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT.METHODSSix patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily ...
Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S   +17 more
openaire   +2 more sources

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]

Yeungnam University Journal of Medicine, 2019
Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang, Heon Ju Lee, Joon Hyuk Choi   +2 more
doaj   +1 more source

Blue nails in chronic myeloid leukemia – Is it usual?

National Journal of Physiology, Pharmacy and Pharmacology, 2020
Nail toxicity is an uncommon cutaneous adverse effect of imatinib mesylate. Here, we have described a 45-year-old female, a diagnosed case of Philadelphia positive chronic myeloid leukemia, who was on imatinib mesylate for the past 3 months and developed
Jaydeep Raj Damor, Jaya Chakravarty, Madhukar Rai, Manaswi Chaubey, Priyanka Kumari, Akash Rai, Ashish Anand Pushpakar, Praveen Kumar Chaturvedi   +7 more
doaj   +1 more source

Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience [PDF]

Vojnosanitetski Pregled, 2010
Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region - Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).
Ćojbašić Irena, Mačukanović-Golubović Lana   +1 more
doaj   +1 more source